

**STUDY OF PRIMORDIAL FOLLICLE, CORPORA  
LUTEA AND *Fmr1* mRNA LEVELS FROM OVARIUM  
OF *Fmr1* GENE PREMUTATION MICE**



**THESIS**

**A thesis submitted for the degree of Master of Biomedical Science majoring  
on Genetic Counseling**

by  
**SANTOSO**  
**G4A007053**

**POST GRADUATE PROGRAM  
DIPONEGORO UNIVERSITY  
SEMARANG  
2010**

**STUDY OF PRIMORDIAL FOLLICLE, CORPORA  
LUTEA AND *Fmr1* mRNA LEVELS FROM OVARIUM  
OF *Fmr1* GENE PREMUTATION MICE**



**THESIS**

**A thesis submitted for the degree of Master of Biomedical Science majoring  
on Genetic Counseling**

By  
**SANTOSO**  
**G4A007053**

**POST GRADUATE PROGRAM  
DIPONEGORO UNIVERSITY  
SEMARANG  
2010**

**THESIS**  
**STUDY OF PRIMORDIAL FOLLICLE, CORPORA LUTEA AND *Fmr1***  
**mRNA LEVELS FROM OVARIUM OF *Fmr1* GENE PREMUTATION**  
**MICE**

By  
SANTOSO

G4A007053

Has been defended in front of the defence committee  
On July 6<sup>th</sup>, 2010  
and has been approved by

**The Netherland**  
Principal Supervisor,

Rob Willemse, PhD

**Indonesia**  
Principal Supervisor,

Prof. Dr. dr. Sarjadi, Sp.PA (K)  
NIP. 130352547  
Supervisor,

dr. Tri Indah Winarni, Msi.Med  
NIP. 132163892

Recognition,  
Head of Master's Degree Program in Biomedical Science  
Post Graduate Program Diponegoro University

Dr. dr. Winarto Sp.MK, SpM(K)  
NIP. 130675157



## **DECLARATION**

I hereby declare that this submission is my own work and that, to the best of my knowledge and belief, it contains no material previously published or written by another person nor material which to a substantial extent has been accepted for the award of any other degree or diploma of the university or other institute of higher learning, except where due acknowledgement is made in the text.

Semarang, July 2010

Santoso

## **ACKNOWLEDGEMENTS**

First of all, I deeply thank God for his blessing and guidance so I could finish my master program. In completion of this thesis, I've got a lot of support from my supervisors, colleagues, friends and family. I would like to express my deepest gratitude to my supervisors Rob Willemsen, PhD, Professor Dr. dr. Sarjadi, SpPA (K), and dr. Tri Indah Winarni, MSi.Med.

My special thanks for Rob Willemsen, PhD, my principal supervisor in The Netherlands, I gratefully acknowledge for sharing your experiences through giving ideas and valuable comments for every chapter of this thesis. To my principal supervisor in Indonesia, Professor Dr. dr. Sarjadi, SpPA (K), thank you for the time you spent for teaching and guiding me and for reading my thesis. My gratitude also to dr. Tri Indah Winarni, MSi.Med for your guidance, endless encouragement and your concern for myself.

I would like to thank to Professor dr. Sultana M.H. Faradz, PhD. Head of Master Biomedical Science Majoring on Genetic Counseling Diponegoro University Semarang, thank you for your kindest attention for me, sharing your experiences. You give me inspiring suggestion and motivation to be the best.

Special thanks for financial support from Bureau of Planning and International Cooperation, Ministry of National Education The republic Indonesia, who fully provided "Beasiswa Unggulan" scholarship for my master degree.

I would like to thanks to Professor dr. Ben Oostra PhD, Chairman of Research Department of Clinical Genetics, Erasmus MC Rotterdam, The Netherlands. Thank you for the opportunity to undertake research in your laboratory, as well as your warm and stimulating interest and friendship. My gratitude also for Renate Hukema, thank you for your patience in training me to do RT and Q PCR, Western Blotting and give me tips to always remember sample id when do RT and Q PCR. Thank you for all of my colleagues at Clinical Genetic Department Erasmus MC, Rotterdam, The Netherlands, especially to Lies-Anne Severijnen, Asma Azmani, Ronald Buijsen, Linda, Christina and Jeannette Lokker.

I would like to extend my acknowledgement to Prof. Dr. dr. Susilo Wibowo, Ms.Med., Sp.And, Rector of Diponegoro University Semarang, dr. Soejoto SpKK (K), Dean of the Faculty of Medicine Diponegoro University Semarang, Dr. dr. Winarto, SpMK, SpM (K) Head of Master's Degree Program in Biomedical Science Post Graduate Program Diponegoro University Semarang, and dr. Kusmiyati D.K, M.Kes, Head of the Biochemistry Department, Faculty of Medicine, Diponegoro University Semarang.

I would like to express my sincere gratitude to my family, my parents and all of my sisters who supported me in many ways until I completed this study.

Last but not least, I would like to thank all others who have contributes to this work.

Semarang, July 2010

Santoso

## ABBREVIATIONS

$\alpha$	: Alfa
<i>AIRE</i>	: Autoimmune Regulator Polyglandular Failure gene
<i>AMH</i>	: Anti Mullerian Hormone
<i>APECED</i>	: Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy
<i>ATM</i>	: Ataxia Telangiectasia Mutated gene
<i>AT2</i>	: Angiotensin II Subtype 2 gene
$\beta$	: Beta
<i>BLM</i>	: RecQL Protein like 3-DNA Helicase gene
Bl/6	: Black 6
<i>BMP15</i>	: Bone Morphogenetic Protein 15 gene
<i>BMP4</i>	: Bone Morphogenetic Protein 4 gene
<i>Cbl</i>	: Cas-Br-M (murine) ecotropic retroviral transforming sequence gene
CGG	: Cytosine-Guanine-Guanine
Ct	: Cycle time
<i>CYP17A1</i>	: 17- $\alpha$ Hydroxylase/17,20-lyase enzyme
$\Delta$	: Delta
<i>dFMR1</i>	: Drosophila FMR1
<i>DIAPH2</i>	: Diaphanous 2 gene
DMSO	: Dimethyl Sulphoxide

DNA	: Deoxyribonucleic acid
dNTP	: Deoxyribonucleotide triphosphate
Dpc	: Days post coitum
EDTA	: Ethylenediaminetetraacetic Acid
<i>EIFB2B-2</i>	: Eukaryotic Translation Initiation Factor 2B, Subunit 2 gene
<i>EIFB2B-4</i>	: Eukaryotic Translation Initiation Factor 2B, Subunit 4 gene
<i>EIFB2B-5</i>	: Eukaryotic Translation Initiation Factor 2B, Subunit 5 gene
exCGG	: Expanded Cytosine Guanin Guanin
FAD	: Fragile X Associated Disorders
FMRP	: Fragile X Mental Retardation Protein
<i>FMR1</i>	: human Fragile X Mental Retardation 1 gene
<i>Fmr1</i>	: mice Fragile X Mental Retardation 1 gene
<i>FOXL2</i>	: Foxhead Transcription Factor gene
<i>FSH</i>	: Follicle Stimulating Hormone
<i>FSHRHI</i>	: FSH Receptor gene
FXS	: Fragile X Syndrome
FXPOF	: Fragile X Associated Premature Ovarian Failure
FXPOI	: Fragile X Associated Primary Ovarian Insufficiency
FXTAS	: Fragile X Associated Tremor Ataxia Syndrome
$\gamma$	: Gamma

<i>GALT</i>	: Galactose 1-Phosphate Uridyl Transferase gene
HCl	: Hydrogen Chloride
HF	: High Fidelity
Homrep	: Homozygous Repeat
HSP	: Stress Response Protein
<i>INHA</i>	: Inhibin $\alpha$ - subunit gene
ko	: Knock Out
<i>LHCGR</i>	: Luteinizing Hormone/Choriogonadotrophine Receptor
<i>Lhx1</i>	: Lim Homeobox 1 gene
<i>LIF</i>	: Leukemia Inhibitory Factor gene
mRNA	: Messanger Ribonucleic acid
NaCl	: Natrium Chloride
PA	: Polyacrilamide
PCR	: Polymerase Chain Reaction
PGCs	: Primordial Germ Cells
POF	: Premature Ovarian Failure
POI	: Primary Ovarian Insufficiency
<i>POLG</i>	: Polymerase $\gamma$
P5	: Postnatal 5 (5-day-old)
P25	: Postnatal 25 (25-day-old)
Q and RT PCR	: Quantitative and Reverse Transcriptase PCR
<i>SCF</i>	: Stem Cell Factor gene
SDS	: Sodium Dodecyl Sulfate

<i>Sf1</i>	: Steroidogenic factor 1 gene
<i>SOX3</i>	: SRY (Sex Determining Region Y) Box 3 gene
<i>STAR</i>	: Steroidogenic Acute Regulatory Protein gene
TBE	: Tris-Borate-EDTA
T1A	: Antibody against human FMRP
UV	: Ultraviolet
wt	: Wild type
<i>Wt1</i>	: Wilm's Tumour 1 gene
<i>XIST</i>	: X (Inactive) Specific Transcript gene
2F5	: Antibody against human FMRP
20wks	: 20 week old
40wks	: 40 week old

## TABLE OF CONTENTS

COVER .....	i
APPROVAL SHEET .....	ii
MONITORING SHEET .....	iii
DECLARATION .....	iv
ACKNOWLEDGEMENT .....	v
ABBREVIATIONS .....	vii
TABLE OF CONTENTS.....	xi
LIST OF TABLES.....	xiv
LIST OF FIGURES .....	xv
LIST OF APPENDICES .....	xvi
ABSTRACT.....	xvii
ABSTRAK.....	xviii
CHAPTER I.	
INTRODUCTION .....	1
1.1. Background.....	1
1.2. Research questions .....	3
1.3. Research purposes .....	4
1.4. Research benefit .....	4
1.5. Research originality.....	4

## CHAPTER 2.

LITERATURE REVIEW .....	6
2.1. Definition and prevalence of the FMR1 premutation.....	6
2.2. Premutation-associated primary ovarian insufficiency .....	7
2.3. Premutation mice is an excellent model to study primary ovarian insufficiency.....	16

## CHAPTER 3.

THEORETICAL FRAMEWORK, CONCEPTUAL FRAMEWORK AND HYPOTHESES .....	20
3.1. Theoretical framework .....	20
3.2. Conceptual framework .....	20
3.3. Hypotheses .....	21

## CHAPTER 4.

RESEARCH METHODS .....	22
4.1. Research field.....	22
4.2. Setting/location and research periods .....	22
4.3. Research design .....	22
4.4. Population and samples.....	22
4.5. Research variables .....	23
4.6. Operational definitions.....	24
4.7. Research protocols .....	25
4.8. Framework of research protocol .....	28
4.9. Data analysis .....	29

4.10. Ethical clearance .....	30
CHAPTER 5.	
RESULTS AND DISCUSSION .....	31
5.1. Results .....	31
5.2. Discussion.....	37
CHAPTER 6.	
CONCLUSION AND RECOMMENDATION.....	42
6.1. Conclusion.....	42
6.2. Recommendation.....	42
REFERENCES .....	43
CURRICULUM VITAE .....	48
APPENDICES .....	53

## **LIST OF TABLE**

1. Table 1.1. Matrix of research originality.
2. Table 2.1. Causes of primary ovarian insufficiency.
3. Table 5.1. Means of primordial follicle number premutation and wt mice in several ages.
4. Table 5.2. Percentage of primordial follicle depletion from P6 to varying age in premutation and wt mice.
5. Table 5.3. Proportion of presence recent corpora lutea from ~20wk premutation mice compared to wt mice.
6. Table 5.4. Proportion of presence recent corpora lutea from ~40wk premutation mice compared to wt mice
7. Table 5.5. Fold change of *Fmr1* mRNA levels from ovaries P25 premutation mice compared to wt mice in the same age.

## **LIST OF FIGURES**

1. Figure 2.1. Expression of *FMR1* in normal women, premutation carriers, and full mutation carriers.
2. Figure 2.2. Relationship of primary ovarian insufficiency by CGG repeat length. Based on a data of 429 *FMR1* premutation carriers and 517 non-carriers.
3. Figure 3.1. Theoretical framework
4. Figure 3.2. Conceptual framework
5. Figure 4.1. Framework of research protocol
6. Figure 5.1. Photomicrograph of ovarian histology of ~20wk premutation mice
7. Figure 5.2. Photomicrograph of ovarian histology of P6 premutation mice
8. Figure 5.3. Primordial follicle population in P6, P25, ~20wk, and ~40wk premutation and wt mice.
9. Figure 5.4. Percentage of primordial follicle depletion from P6 to varying age in premutation and wt mice.
10. Figure 5.5. Photomicrograph of ovarian histology of premutation mice.

## **LIST OF APPENDICES**

1. Appendix 1. Database of Primordial Follicle number, presence of recent corpora lutea, and Fmr1 mRNA from premutation mice and wild type.
2. Appendix 2. Output of SPSS analysis results.
3. Appendix 3. Ethical Clearance from ErasmusMC Erasmus University Rotterdam, The Netherland

## Abstract

**Background :** The *FMR1* gene involves in fragile X-associated disorders (FAD), including the fragile X mental retardation syndrome, primary ovarian insufficiency (POI) and Fragile X associated tremor/ataxia syndrome. Primary ovarian insufficiency (POI) affect on 13-26% female premutation carrier, characterized by early depletion of ovarian follicles before the age of 40 years. The underlying mechanisms of POI are still unclear. This study focuses on number of primordial follicles, ovulation and ovarian *Fmr1* mRNA levels in *Fmr1* gene premutation mice as animal models.

**Method :** This research was a cross sectional study using a *Fmr1* gene premutation mice model (exCGG mice) and wt mice. The number of primordial follicles were determined at different ages (P6, P25, ~20wk, and ~40wk). The presence of recent corpora lutea (CL) were determined at ~20wk and ~40wk. *Fmr1* mRNA levels in ovaries from P25 premutation mice were determined and compared to wild type (wt) mice.

**Results :** Approximately a four fold elevated level of *Fmr1* mRNA was found in ovaries of premutation mice. No differences in number of primordial follicles was found in ovaries from P6 and ~20wk premutation mice compared to wt mice ( $p=0.052$  and  $p=0.515$ , respectively). Significant higher number of primordial follicles was found at P25, and ~40wk premutation mice compared to wt mice ( $p=0.018$ , and  $0.006$ , respectively). Furthermore reduced ovulation, determined by presence of recent corpora lutea, in 20 and 40-week-old premutation mice was found.

**Conclusion :** The fragile X premutation does not cause a reduction in the initial pool of primordial follicles from birth but might be involved in mechanisms influencing the folliculogenesis results in decreased ovulation..

---

**Keyword :** Primary ovarian insufficiency (POI), *FMR1* gene, FMRP, *FMR1* mRNA, primordial follicle, folliculogenesis

## **Abstrak**

**Latar Belakang** : Gen *FMR1* merupakan penyebab *Fragile X-associated disorders* (FAD), yang meliputi *Fragile X Syndrome* (FXS), *Primary ovarian insufficiency* (POI) dan *tremor/ataxia syndrome*. 13-26% wanita pembawa alel premutasi mengalami POI, yang ditandai dengan berkurangnya jumlah cadangan folikel dalam ovarium sebelum berusia 40 tahun, sementara itu patogenesis dari POI pada wanita premutasi sampai sekarang masih belum diketahui. Penelitian ini bertujuan untuk mengetahui jumlah cadangan folikel primordial, ovulasi dan konsentrasi *Fmr1 mRNA* pada ovarium tikus premutasi gen *Fmr1*.

**Metode** : Penelitian ini merupakan penelitian *cross sectional* dengan menggunakan tikus premutasi dan *wild type* (wt). Jumlah folikel primordial dihitung dari kelompok tikus pada usia yang berbeda (6 hari, 25 hari, ~20 minggu, dan ~40 minggu). Adanya ovulasi dideteksi dengan adanya *recent corpora lutea* pada kelompok tikus usia ~20 minggu dan ~40 minggu. Konsentrasi *Fmr1 mRNA* diukur dari ovarium kelompok tikus premutasi usia 25 hari yang dibandingkan dengan kelompok wt.

**Hasil** : Terdapat peningkatan empat kali lipat konsentrasi *Fmr1 mRNA* pada ovarium tikus premutasi dibandingkan dengan kelompok wt. Tidak terdapat perbedaan jumlah folikel primordial pada kelompok tikus premutasi usia 6 hari ( $p=0.052$ ) dan ~20 minggu ( $p=0.515$ ) dan terdapat peningkatan jumlah folikel primordial pada usia 25 hari ( $p=0.018$ ) dan ~40 minggu ( $p=0.006$ ). Selain itu, ditemukan penurunan jumlah ovulasi yang dideteksi dengan adanya *recent corpora lutea*, pada kelompok usia ~20 minggu dan ~40 minggu.

**Kesimpulan** : Premutasi gen *Fmr1* tidak menyebabkan pengurangan jumlah folikel primordial. Ditemukan gangguan folikulogenesis yang menyebabkan pengurangan jumlah ovulasi pada tikus premutasi.

---

Kata Kunci : Primary ovarian insufficiency (POI), gen *FMR1*, FMRP, *FMR1 mRNA*, folikel primordial, folikulogenesis.